<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85681">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916850</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-110-NRM</org_study_id>
    <secondary_id>LX4211.110</secondary_id>
    <nct_id>NCT01916850</nct_id>
  </id_info>
  <brief_title>Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects</brief_title>
  <official_title>A Phase 1b, Single-center, Double-blind, Randomized, Placebo-controlled Study on the Safety, Tolerability, and Pharmacokinetic Effects of Multiple Doses of LX4211 400 mg qd and LX4211 800 mg qd in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of multiple
      oral doses of LX4211 400 mg and LX4211 800 mg (administered once daily for 10 consecutive
      days) in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to Day 10</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>Days 1 through 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LX4211 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg of LX4211 administered once daily for 10 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LX4211 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg of LX4211 administered once daily for 10 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo administered once daily for 10 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211 400 mg</intervention_name>
    <arm_group_label>LX4211 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211 800 mg</intervention_name>
    <arm_group_label>LX4211 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211 Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects ≥ 18 to ≤ 55 years of age

          -  Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mm
             Hg; diastolic blood pressure, 50-90 mm Hg; heart rate, 50-100 bpm

          -  Body mass index (BMI) ≥18 and ≤35 kg/sq m

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Use of any medication (prescription, over-the-counter, herbal tea, or supplements)
             within 5 days of dosing

          -  Use of any investigational agent or study treatment within 30 days of dosing

          -  Use of any protein or antibody-based therapeutic agents within 3 months of Screening

          -  Prior exposure to LX4211

          -  Use of cigarettes or any tobacco products within 2 months prior to Screening and
             while participating in the study

          -  History of bariatric surgery or any other gastrointestinal surgery that may induce
             malabsorption

          -  History of any major surgery within 6 months of Screening

          -  History of any hypersensitivity to the inactive components of LX4211

          -  History of renal disease or significantly abnormal kidney function tests

          -  History of hepatic disease or significantly abnormal liver function tests

          -  History of any active infection within 14 days prior to Day 1

          -  History of alcohol or substance abuse within 2 years prior to Day 1

          -  Donation or loss of &gt;400 mL of blood or blood product within 3 months of dosing

          -  Positive urine glucose at Screening

          -  Positive urine screen for drugs of abuse, or urine test for alcohol at Screening or
             Day -1

          -  Inability or difficulty swallowing pills

          -  Unable or unwilling to communicate or cooperate with the Investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ikenna (Ike) Ogbaa, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 28, 2013</lastchanged_date>
  <firstreceived_date>July 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
